Sarepta stock: buy or sell?
June 26th, 2019
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases.
Should I buy Sarepta stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Check the only buy setup that matches with Sarepta stock now:
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||Yes|
|100d MA crossing up 200d MA||No|
Is Sarepta Therapeutics stock a buy?
Banks and financial institutions publish stock ratings everyday.At Stocks2.com, we detected 14 ratings published for SRPT stock in the last 30 days. The general sentiment of these ratings is bullish for SRPT stock, with 13 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-5-9||Royal Bank of Canada||n/a||Outperform|
|2019-3-28||Piper Jaffray Companies||n/a||Overweight|
|2019-3-12||BMO Capital Markets||n/a||Outperform|
|2019-3-11||Credit Suisse Group||n/a||Outperform|
|2019-1-17||Royal Bank of Canada||n/a||Outperform|
Sarepta stock analysis
After sliding for 4 sessions, Wednesday Sarepta skyrocketed a brilliant 3.37%, closing at $128.34.
After sliding for 4 days, Wednesday Sarepta skyrocketed a brilliant 3.37%, closing at $128.34. Today SRPT price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. SRPT shows a short term strength with several rising tops and rising bottoms. In the very short term, yesterday it marked a new bottom at $123.79 that should act a support if Sarepta starts a trading flat base in the range of $123.79 - $135.71 If Sarepta Therapeutics breakouts over $135.71 with average or higher volume, this would be a signal that the uptrend resumes.
After boosting a dazzling 7.94% in a week last week, Sarepta Therapeutics closed this week at $128.34 and decreased an unpleasant -1.19%. Late May SRPT plunged a bloodcurdling -6.14% in just one week.
Since last week when SRPT stock price broke up the SMA40w line, it gained $8.77 (7.33%).
Sarepta stock price history
Sarepta stock went public on June 4th, 1997 with a price of $42.751. Since then, SRPT stock surged a 200.20%, with a yearly average of 9.10%. If you had invested right after SRPT's IPO a $1,000 in Sarepta stock in 1997, it would worth $2,002.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Sarepta stock historical price chart
SRPT stock reached 52-week highs on October at $165.87, and all-time highs 2018-06-19 with a price of 176.5.
Sarepta stock price target is $207.50How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We have 12 price forecasts for SRPT stock released in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-6-17||HC Wainwright||Set Price Target||n/a||$267.00||-|
|2019-5-9||Royal Bank of Canada||Lowers Target||$191.00||$188.00||-1.6%|
|2019-5-14||Morgan Stanley||Lowers Target||$169.00||$165.00||-2.4%|
|2019-3-4||Morgan Stanley||Raises Target||$161.00||$169.00||5%|
|2019-3-28||Piper Jaffray Companies||Raises Target||$200.00||$208.00||4%|
|2019-3-11||Credit Suisse Group||Reiterates||$189.00||$207.00||9.5%|
|2019-1-17||Royal Bank of Canada||Reiterates||n/a||$164.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Sarepta Therapeutics reported its latest financial data, posting an astounding growth for the Earnings per Share (EPS). Experts expected $-1.08 per share, but Sarepta posted $-2.05.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Sarepta Therapeutics annual sales climbed an exceptional 94.74% to $301.03 million USD from $154.58 marked in 2017. On the other hand, its earnings margin (compared to sales) collapsed to -120.22%, that is $-361.92 million.
|2013||$14 M||-||$-111.99 M-787.6%||-|
|2014||$9.76 M||-31.39%||$-135.79 M-1391.7%||21.25%|
|2015||$1.25 M||-87.16%||$-220.03 M-17560.3%||62.04%|
|2016||$5.42 M||332.64%||$-267.27 M-4930.2%||21.47%|
|2017||$155 M||2,751.58%||$-50.69 M-32.8%||-81.03%|
|2018||$301 M||94.74%||$-361.92 M-120.2%||614.01%|
Quarterly financial resultsSarepta Therapeutics reported $84.42 M in sales for 2018-Q4, a 7.55% improvement compared to previous quarter. Reported quarter earnings marked $-140.90 million with a profit margin of -166.91%. Profit margin plummed a -69.57% compared to previous quarter when profit margin was -97.33%. When comparing sales to same quarter last year, Sarepta sales marked a super good increase and rocketed a 47.38%. Looking back to recent quarterly results, Sarepta Therapeutics posted 7 positive quarters in a row.
|2017-Q1||$16 M||-||$84.09 M514.6%||-|
|2017-Q2||$35 M||114.26%||$-63.05 M-180.1%||-174.98%|
|2017-Q3||$46 M||31.25%||$-47.73 M-103.9%||-24.30%|
|2017-Q4||$57 M||24.65%||$-24.00 M-41.9%||-49.72%|
|2018-Q1||$65 M||12.79%||$-35.36 M-54.7%||47.36%|
|2018-Q2||$74 M||13.81%||$-109.27 M-148.6%||208.99%|
|2018-Q3||$78 M||6.74%||$-76.39 M-97.3%||-30.09%|
|2018-Q4||$84 M||7.55%||$-140.90 M-166.9%||84.43%|
Sarepta ownershipWhen you are planning to buy a company, it's always worth to review its ownership structure.
Sarepta shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 5.25% of all shares.
Bearish positions for SRPT stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Sarepta:
|Market cap||$9.5 B||$7.4 B||$390.5 M||$84.7 B||$418.3 M|
|Total shares||74.2 M||106.5 M||110.3 M||1,270.0 M||96.8 M|
|Float shares||70.3 M||105.6 M||60.2 M||1,270.0 M||1.8 M|
|- Institutional holdings (%)||92.5%||88.2%||93.6%||82.6%||6.1%|
|- Insider holdings (%)||5.2%||10.8%||1.0%||0.7%||12.8%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Wednesday, June 26th, 2019|
|Day range||$124.61 - $129.43|
|Average true range||$4.93|
|50d mov avg||$120.66|
|100d mov avg||$125.88|
|200d mov avg||$126.90|
Sarepta performanceTo better understand Sarepta Therapeutics performance you must compare its gains with other related stocks in same sector or industry. We chose Alnylam Pharmaceuticals, BioCryst Pharmaceuticals, Gilead Sciences, Hemispherx BioPharma, Ionis Pharmaceuticals, NewLink Genetics, PTC Therapeutics and Retrophin as the bechmarking frame for Sarepta stock.
Sarepta competitorsOne check before trading any stock is to have a look a list of its competitors, in this case for Sarepta Therapeutics. We picked 8 companies as Sarepta Therapeutics competitors as they are in the same industry or have similar market objectives.
- Alnylam Pharmaceuticals (ALNY)
- BioCryst Pharmaceuticals (BCRX)
- Gilead Sciences (GILD)
- Hemispherx BioPharma (HEB)
- Ionis Pharmaceuticals (IONS)
- NewLink Genetics (NLNK)
- PTC Therapeutics (PTCT)
- Retrophin (RTRX)
Latest Sarepta stock news
- Seeking AlphaSarepta: When You Sell Too Early And Want Back InJune 25, 2019
- Seeking AlphaSarepta Therapeutics: Judgement Day ComethJune 24, 2019
- Seeking AlphaSarepta: Buy The Pfizer SelloffMay 1, 2019
- Seeking AlphaWhat's Wrong With Sarepta Therapeutics?April 1, 2019
- Seeking AlphaSarepta Looks To Remain The Leader In DMD Treatment With Latest Gene Therapy DataMarch 27, 2019